ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Resurgence and seasonal patterns of RSV-B during the COVID-19 era: an 18-year retrospective hospital-based study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Decoupling of Respiratory Virus Positivity and Host Inflammatory Response: A 16-Year Longitudinal Study.Microorganisms · 2026Article
- Monitoring of RSV-A and RSV-B Circulation in Poland Across Three Post-Pandemic Seasons (2022-2025).Viruses · 2026Article
- Declined Circulation and Seasonal Shifts of Human Coronavirus 229E in the Republic of Korea: Implications for Respiratory Virus Surveillance.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiological Shifts in Respiratory Virus Infections Among Older Adults (≥65 Years) Before and After the COVID-19 Pandemic: An 18-Year Retrospective Study in the Republic of Korea.Microorganisms · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory infections, particularly in infants, older adults, and immunocompromised individuals. In this study, we aimed to characterize the epidemiology of RSV subtype B (RSV-B), which remains relatively understudied compared with subtype A despite its clinical significance. We conducted a retrospective analysis of laboratory-confirmed RSV-B infections over 18 years (2007-2024) at a tertiary hospital in South Korea. The dataset included 23,284 cases analyzed for age distribution, seasonality, sex differences, and the impact of the coronavirus disease 2019 (COVID-19) pandemic. The highest positivity rate was observed in infants under 1 year (12.7%, p < 0.001), followed by ages 1-19 years (6.9%). RSV-B incidence peaked in winter (11.9%) and autumn (8.7%), with significant seasonal variation (p < 0.001). No statistically significant sex-based difference was observed (male: 6.1%, female: 6.7%; p = 0.102). Positivity rates declined markedly during the COVID-19 pandemic (2019-2022), likely due to non-pharmaceutical interventions. These findings clarify RSV-B's distinct epidemiology and underscore the need for subtype-specific surveillance, targeted vaccination, and adaptable public health strategies. This study provides evidence to improve outbreak prediction, identify high-risk groups, and optimize clinical and preventive responses to RSV-B.
Indexed as
Identifiers
40434592What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.